1Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukemia : lesson to be learned from the laboratory. Br J Haematol, 2001, 113(1):11-23.
2Mes-Masson AM, McLaughlin J, Daley GQ, et al. Overlapping cDNA clones define the complete coding region for the P210e-ab1 gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chrosome. Proc Natl Acad Sci U S A,1986, 83 (24):9768- 9772.
3Daley GQ, Mclaughlin J, Witte ON, et al. The CML-specific P210 bcr/abl protein, unlike v-abl, dose not transform NIH/3T3 fibroblasts. Science, 1987, 237:532-535.
4Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science, 1990, 247:824-830.
5Daley GQ, Van Etten RA, Baltimore D. Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci U SA, 1991, 88(24):11335-11338.
6Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A,1993, 90(8):3755-3759.
7Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood, 1998, 92 (10): 3829-3840.
8Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood,1998, 92(10): 3780-3792.
9Wolff NC, Ilaria RL. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinaseinhibitor STI571. Blood, 2001, 98(9): 2808-2816.
10Wolff NC, Richardson JA, Egorin M, et al. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood, 2003, 101 (12) : 5010-5013
